secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0000950170-25-005104
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences prelim Q4 2024 rev $18.9-19.1M (+1% YoY); Surgical Glaucoma +9%
------------------------------------------------------------------------------

- Surgical Glaucoma revenue $18.7-18.8M (+9% YoY at midpoint); Dry Eye rev $0.2-0.3M vs $1.6M prior year.
- Full year 2024 total revenue $79.7-79.9M (-2% YoY); cash and equivalents ~$120M; $1.4M generated in Q4.
- New LCDs by five Medicare contractors effective mid-November restricted MIGS coverage, impacting results.
- Company plans to achieve cash flow breakeven without additional equity capital; FY 2024 cash used $18.1M down from $46.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025005104/0000950170-25-005104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025005104/sght-20250114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-005104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer